Karp, J E <br/><br/>
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.  [electronic resource] 

 -  Blood  Jun 2001 
 - 3361-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Standard No.: </label>10.1182/blood.v97.11.3361  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Alkyl and Aryl Transferases--antagonists & inhibitors<br/>Bone Marrow--metabolism<br/>Cohort Studies<br/>Dose-Response Relationship, Drug<br/>Enzyme Activation--drug effects<br/>Enzyme Inhibitors--adverse effects<br/>Farnesyltranstransferase<br/>Female<br/>Genes, ras<br/>Humans<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Middle Aged<br/>Mitogen-Activated Protein Kinase 1--metabolism<br/>Mitogen-Activated Protein Kinase 3<br/>Mitogen-Activated Protein Kinases--metabolism<br/>Mutation<br/>Phosphorylation<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Protein Prenylation<br/>Quinolones--adverse effects<br/>Recurrence<br/>Remission Induction<br/>Treatment Outcome